Download PDF
Hamostaseologie
DOI: 10.1055/a-2347-6507
Review Article

Bleeding Risk in Patients with Cancer

Cornelia Englisch
1   Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria
,
Nikola Vladic
1   Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria
,
Cihan Ay
1   Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria
2   Department of Obstetrics, Gynecology and Perinatal Medicine, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The hemostatic system and cancer display a tight interconnection, and hemostatic imbalance frequently occurs in patients with cancer. While extensive knowledge about thrombotic risk has been generated, less is known about bleeding risk and associated risk factors. However, bleeding risk is of high significance as patients with cancer frequently receive therapeutic anticoagulation for various indications and/or are candidates for primary thromboprophylaxis. The risk of bleeding in patients with cancer is variable and difficult to assess in clinical practice. Certain clinical settings such as hospitalization, specific underlying risk factors (e.g., tumor type), and medications (e.g., anticoagulation) can contribute to the individual bleeding risk of a patient with cancer. In addition, some dynamic factors such as platelet count or kidney function have an impact. Particularly, data on baseline risk of bleeding are lacking to allow for risk assessment in cancer patients without anticoagulation. In contrast, risk assessment models for the prediction of bleeding events in cancer patients receiving anticoagulation have been developed; however, these have yet to be validated. The recognition of the importance of bleeding risk in cancer patients is growing, leading to an increasing number of studies investigating and reporting bleeding complications. As study designs and reporting of bleeding events vary, it is challenging to offer a clear synthesis of evidence. In this narrative review, we provide an overview of currently available data about incidence, risk factors, and clinical impact of bleeding events in patients with cancer, and critically review risk assessment models for bleeding in cancer patients during anticoagulant therapy.

Keywords

hemorrhage - major bleeding - cancer - risk


Publication History

Received: 18 April 2024

Accepted: 01 July 2024

Article published online:
03 September 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mantha S. Bleeding disorders associated with cancer. Cancer Treat Res 2019; 179: 191-203
    CrossrefPubMedGoogle Scholar
  • 2 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Falanga A, Ay C, Di Nisio M. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34 (05) 452-467
    CrossrefPubMedGoogle Scholar
  • 4 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023; 41 (16) 3063-3071
    CrossrefPubMedGoogle Scholar
  • 5 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022; 23 (07) e334-e347
    CrossrefPubMedGoogle Scholar
  • 6 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
    CrossrefPubMedGoogle Scholar
  • 7 Agnelli G, Gussoni G, Bianchini C. et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10 (10) 943-949
    CrossrefPubMedGoogle Scholar
  • 8 Agnelli G, George DJ, Kakkar AK. et al; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (07) 601-609
    CrossrefPubMedGoogle Scholar
  • 9 Khorana AA, Francis CW, Kuderer NM. et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res 2017; 151: 89-95
    CrossrefPubMedGoogle Scholar
  • 10 Pelzer U, Opitz B, Deutschinoff G. et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 2015; 33 (18) 2028-2034
    CrossrefPubMedGoogle Scholar
  • 11 Carrier M, Abou-Nassar K, Mallick R. et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
    CrossrefPubMedGoogle Scholar
  • 12 Khorana AA, Soff GA, Kakkar AK. et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380 (08) 720-728
    CrossrefPubMedGoogle Scholar
  • 13 Kakkar AK, Levine MN, Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004; 22 (10) 1944-1948
    CrossrefPubMedGoogle Scholar
  • 14 Klerk CP, Smorenburg SM, Otten HM. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23 (10) 2130-2135
    CrossrefPubMedGoogle Scholar
  • 15 van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011; 29 (15) 2071-2076
    CrossrefPubMedGoogle Scholar
  • 16 Schünemann HJ, Ventresca M, Crowther M. et al. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematol 2020; 7 (10) e746-e755
    CrossrefPubMedGoogle Scholar
  • 17 Ohashi Y, Ikeda M, Kunitoh H. et al. One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: results from the Cancer-VTE Registry. Thromb Res 2022; 213: 203-213
    CrossrefPubMedGoogle Scholar
  • 18 Englisch C, Moik F, Steiner D. et al. PB0919 high rates of bleeding in unselected patients with cancer: results from a prospective cohort study. Res Pract Thromb Haemost 2023; 7: 101768
    CrossrefPubMedGoogle Scholar
  • 19 Wang TF, Carrier M, Carney BJ, Kimpton M, Delluc A. Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis. Thromb Res 2023; 227: 8-16
    CrossrefPubMedGoogle Scholar
  • 20 Di Nisio M, Candeloro M, Rutjes AWS, Galli V, Tritto M, Porreca E. Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an acute medical illness. Thromb Res 2018; 169: 44-49
    CrossrefPubMedGoogle Scholar
  • 21 Tardy B, Picard S, Guirimand F. et al. Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study. J Thromb Haemost 2017; 15 (03) 420-428
    CrossrefPubMedGoogle Scholar
  • 22 Yamashita Y, Morimoto T, Amano H. et al; COMMAND VTE Registry Investigators. Anticoagulation therapy for venous thromboembolism in the real world – from the COMMAND VTE Registry. Circ J 2018; 82 (05) 1262-1270
    CrossrefPubMedGoogle Scholar
  • 23 Sakamoto J, Yamashita Y, Morimoto T. et al; COMMAND VTE Registry Investigators. Cancer-associated venous thromboembolism in the real world – from the COMMAND VTE Registry. Circ J 2019; 83 (11) 2271-2281
    CrossrefPubMedGoogle Scholar
  • 24 Bleker SM, van Es N, van Gils L. et al. Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review. Thromb Res 2016; 140 (Suppl. 01) S81-S88
    CrossrefPubMedGoogle Scholar
  • 25 Streiff MB, Milentijevic D, McCrae K. et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol 2018; 93 (05) 664-671
    CrossrefPubMedGoogle Scholar
  • 26 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 27 Prandoni P, Trujillo-Santos J, Surico T, Dalla Valle F, Piccioli A, Monreal M. RIETE Investigators. Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry. Haematologica 2008; 93 (09) 1432-1434
    CrossrefPubMedGoogle Scholar
  • 28 Chatani R, Yamashita Y, Morimoto T. et al; COMMAND VTE Registry-2 Investigators. Cancer-associated venous thromboembolism in the direct oral anticoagulants era: insight from the COMMAND VTE Registry-2. Thromb Res 2024; 234: 86-93
    CrossrefPubMedGoogle Scholar
  • 29 Bertoletti L, Madridano O, Jiménez D. et al. Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020. JACC Cardiooncol 2023; 5 (06) 758-772
    CrossrefPubMedGoogle Scholar
  • 30 Lee AY, Levine MN, Baker RI. et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 31 Lee AYY, Kamphuisen PW, Meyer G. et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 32 Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136 (03) 582-589
    CrossrefPubMedGoogle Scholar
  • 33 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedGoogle Scholar
  • 34 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 35 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 36 Schrag D, Uno H, Rosovsky R. et al; CANVAS Investigators. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA 2023; 329 (22) 1924-1933
    CrossrefPubMedGoogle Scholar
  • 37 Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost 2020; 4 (04) 550-561
    CrossrefPubMedGoogle Scholar
  • 38 Francis CW, Kessler CM, Goldhaber SZ. et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13 (06) 1028-1035
    CrossrefPubMedGoogle Scholar
  • 39 Di Nisio M, van Es N, Carrier M. et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost 2019; 17 (11) 1866-1874
    CrossrefPubMedGoogle Scholar
  • 40 Moik F, Colling M, Mahé I, Jara-Palomares L, Pabinger I, Ay C. Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: a systematic review. J Thromb Haemost 2022; 20 (03) 619-634
    CrossrefPubMedGoogle Scholar
  • 41 Nishimoto Y, Yamashita Y, Kim K. et al; COMMAND VTE Registry Investigators. risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism – from the COMMAND VTE Registry. Circ J 2020; 84 (11) 2006-2014
    CrossrefPubMedGoogle Scholar
  • 42 Trujillo-Santos J, Martos FM, Font C. et al. Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Heliyon 2017; 3 (01) e00229
    CrossrefPubMedGoogle Scholar
  • 43 Grdinic AG, Radovanovic S, Gleditsch J. et al. Developing a machine learning model for bleeding prediction in patients with cancer-associated thrombosis receiving anticoagulation therapy. J Thromb Haemost 2024; 22 (04) 1094-1104
    CrossrefPubMedGoogle Scholar
  • 44 Chee CE, Ashrani AA, Marks RS. et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 2014; 123 (25) 3972-3978
    CrossrefPubMedGoogle Scholar
  • 45 Zakai NA, Walker RF, MacLehose RF, Adam TJ, Alonso A, Lutsey PL. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism. J Thromb Haemost 2018; 16 (12) 2403-2412
    CrossrefPubMedGoogle Scholar
  • 46 Søgaard M, Nielsen PB, Skjøth F, Kjaeldgaard JN, Larsen TB. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: a nationwide cohort study. Cancer Med 2019; 8 (03) 1044-1053
    CrossrefPubMedGoogle Scholar
  • 47 Hannevik TL, Brekke J, Enden T. et al. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. Thromb Res 2020; 196: 238-244
    CrossrefPubMedGoogle Scholar
  • 48 Girard P, Laporte S, Chapelle C. et al. Failure of the Ottawa score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE Cohort Study. Thromb Haemost 2022; 122 (01) 151-157
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Cohen AT, Wallenhorst C, Choudhuri S, Nassar A, Pollock KG, Martinez C. A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer. Thromb Haemost 2024; 124 (04) 324-336
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Lecumberri R, Ruiz-Artacho P, Tzoran I. et al; RIETE Investigators. Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors. Thromb Haemost 2022; 122 (09) 1594-1602
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Poénou G, Tolédano E, Helfer H. et al. Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events. Front Cardiovasc Med 2023; 10: 1132156
    CrossrefPubMedGoogle Scholar
  • 52 Trujillo-Santos J, Nieto JA, Ruíz-Gamietea A. et al; RIETE Investigators. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 (Suppl. 02) S58-S61
    CrossrefPubMedGoogle Scholar
  • 53 Ay C, Grilz E, Nopp S. et al. Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study. Res Pract Thromb Haemost 2022; 7 (01) 100026
    CrossrefPubMedGoogle Scholar
  • 54 Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis. Thromb Haemost 2020; 120 (02) 314-321
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Pastori D, Marang A, Bisson A. et al. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Cancer 2021; 127 (12) 2122-2129
    CrossrefPubMedGoogle Scholar
  • 56 Ajabnoor AM, Parisi R, Zghebi SS. et al. Common cancer types and risk of stroke and bleeding in patients with nonvalvular atrial fibrillation: a population-based study in England. J Am Heart Assoc 2023; 12 (19) e029423
    CrossrefPubMedGoogle Scholar
  • 57 Raposeiras Roubín S, Abu Assi E, Muñoz Pousa I. et al. Incidence and predictors of bleeding in patients with cancer and atrial fibrillation. Am J Cardiol 2022; 167: 139-146
    CrossrefPubMedGoogle Scholar
  • 58 Barbarawi M, Barbarawi O, Corcoran J. et al. Efficacy and safety of the non-vitamin K antagonist oral anticoagulant among patients with nonvalvular atrial fibrillation and cancer: a systematic review and network meta-analysis. Curr Probl Cardiol 2022; 47 (11) 101346
    CrossrefPubMedGoogle Scholar
  • 59 Xi S, Liu C, Yu S, Qiu J, He S, Yi Z. Comparison of performances among four bleeding-prediction scores in elderly cancer patients with venous thromboembolism. Hamostaseologie 2023; 43 (04) 281-288
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Patell R, Gutierrez A, Rybicki L, Khorana AA. Identifying predictors for bleeding in hospitalized cancer patients: a cohort study. Thromb Res 2017; 158: 38-43
    CrossrefPubMedGoogle Scholar
  • 61 Osataphan S, Patell R, Chiasakul T, Khorana AA, Zwicker JI. Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Adv 2021; 5 (08) 2055-2062
    CrossrefPubMedGoogle Scholar
  • 62 Iyengar V, Agrawal S, Chiasakul T. et al. Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review. J Thromb Haemost 2024; 22 (02) 423-429
    CrossrefPubMedGoogle Scholar
  • 63 Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost 2016; 14 (09) 1736-1740
    CrossrefPubMedGoogle Scholar
  • 64 Giustozzi M, Proietti G, Becattini C, Roila F, Agnelli G, Mandalà M. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 2022; 6 (16) 4873-4883
    CrossrefPubMedGoogle Scholar
  • 65 Becattini C, Giustozzi M, Portillo J. et al; RIETE Investigators. Acute venous thromboembolism in patients with brain cancer: clinical course. Res Pract Thromb Haemost 2023; 7 (06) 102172
    CrossrefPubMedGoogle Scholar
  • 66 Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood 2017; 129 (25) 3379-3385
    CrossrefPubMedGoogle Scholar
  • 67 Gould MK, Garcia DA, Wren SM. et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e227S-e277S
    CrossrefPubMedGoogle Scholar
  • 68 Kakkar VV, Cohen AT, Edmonson RA. et al; The Thromboprophylaxis Collaborative Group. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341 (8840) 259-265
    CrossrefPubMedGoogle Scholar
  • 69 Hébert J, Eltonsy S, Gaudet J, Jose C. Incidence and risk factors for anastomotic bleeding in lower gastrointestinal surgery. BMC Res Notes 2019; 12 (01) 378
    CrossrefPubMedGoogle Scholar
  • 70 Lavikainen LI, Guyatt GH, Luomaranta AL. et al; ROTBIGGS Investigators. Risk of thrombosis and bleeding in gynecologic cancer surgery: systematic review and meta-analysis. Am J Obstet Gynecol 2024; 230 (04) 403-416
    CrossrefPubMedGoogle Scholar
  • 71 Wiegers HMG, Schaafsma M, Guman NAM. et al. Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis. J Thromb Haemost 2023; 21 (02) 294-302
    CrossrefPubMedGoogle Scholar
  • 72 Rich JM, Elkun Y, Geduldig J. et al. Outcomes from a prospectively implemented protocol using apixaban after robot-assisted radical cystectomy. BJU Int 2023; 132 (04) 390-396
    CrossrefPubMedGoogle Scholar
  • 73 Ortiz RM, Golijanin B, O'Rourke TK. et al. Direct oral anticoagulants for venous thromboembolism prophylaxis following robot-assisted radical cystectomy: a retrospective feasibility study at a single academic medical center. Urology 2021; 156: 154-162
    CrossrefPubMedGoogle Scholar
  • 74 Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial). Clin Appl Thromb Hemost 2022; 28: 10 760296221132556
    CrossrefPubMedGoogle Scholar
  • 75 Guntupalli SR, Brennecke A, Behbakht K. et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open 2020; 3 (06) e207410-e207410
    CrossrefPubMedGoogle Scholar
  • 76 Becattini C, Pace U, Pirozzi F. et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood 2022; 140 (08) 900-908
    CrossrefPubMedGoogle Scholar
  • 77 Laccourreye O, Malinvaud D, Garcia D. et al. Postoperative hemorrhage after transoral oropharyngectomy for cancer of the lateral oropharynx. Ann Otol Rhinol Laryngol 2015; 124 (05) 361-367
    CrossrefPubMedGoogle Scholar
  • 78 Pollei TR, Hinni ML, Moore EJ. et al. Analysis of postoperative bleeding and risk factors in transoral surgery of the oropharynx. JAMA Otolaryngol Head Neck Surg 2013; 139 (11) 1212-1218
    CrossrefPubMedGoogle Scholar
  • 79 Eisen LA, Narasimhan M, Berger JS, Mayo PH, Rosen MJ, Schneider RF. Mechanical complications of central venous catheters. J Intensive Care Med 2006; 21 (01) 40-46
    CrossrefPubMedGoogle Scholar
  • 80 Hakem R, Soudet S, Diouf M, Sevestre MA. Venous thrombosis recurrence after catheter-related upper extremity deep venous thrombosis in cancer patients: a retrospective analysis. Angiology 2024; 75 (07) 658-665
    CrossrefPubMedGoogle Scholar
  • 81 Porfidia A, Cammà G, Coletta N. et al. A single center retrospective cohort study comparing different anticoagulants for the treatment of catheter-related thrombosis of the upper extremities in women with gynecologic and breast cancer. Front Cardiovasc Med 2022; 9: 880698
    CrossrefPubMedGoogle Scholar
  • 82 Xu J, Wang G, Chen X, Shen Y, Wang X, Wang H. Efficacy and safety of rivaroxaban for the treatment of PICC-related upper extremity deep vein thrombosis in cancer patients: a retrospective study. Thromb J 2023; 21 (01) 15
    CrossrefPubMedGoogle Scholar
  • 83 Kovacs MJ, Wells PS, Rodger MA. et al. A prospective study of apixaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients: catheter 3. Blood 2022; 140 (Suppl. 01) 1245-1246
    CrossrefPubMedGoogle Scholar
  • 84 Mahé I, Agnelli G, Ay C. et al. Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT Study. Thromb Haemost 2022; 122 (04) 646-656
    Article in Thieme ConnectPubMedGoogle Scholar
  • 85 McBane II RD, Loprinzi CL, Zemla T. et al; EVE Trial Investigators. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. J Thromb Haemost 2024; 22 (06) 1704-1714
    CrossrefPubMedGoogle Scholar
  • 86 Woodruff S, Lee AYY, Carrier M, Feugère G, Abreu P, Heissler J. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. J Thromb Thrombolysis 2019; 47 (04) 495-504
    CrossrefPubMedGoogle Scholar
  • 87 Becattini C, Bauersachs R, Maraziti G. et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica 2022; 107 (07) 1567-1576
    CrossrefPubMedGoogle Scholar
  • 88 Bauersachs R, Lee AYY, Kamphuisen PW. et al; CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism - analysis of the CATCH Study. Thromb Haemost 2018; 118 (05) 914-921
    Article in Thieme ConnectPubMedGoogle Scholar
  • 89 Kamphuisen PW, Lee AYY, Meyer G. et al; CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. J Thromb Haemost 2018; 16 (06) 1069-1077
    CrossrefPubMedGoogle Scholar
  • 90 Patell R, Hsu C, Shi M. et al. Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer. Haematologica 2024; 109 (06) 1849-1856
    PubMedGoogle Scholar
  • 91 Mulder FI, Bosch FTM, Carrier M. et al. Growth differentiation factor-15 for prediction of bleeding in cancer patients. J Thromb Haemost 2022; 20 (01) 138-144
    CrossrefPubMedGoogle Scholar
  • 92 Vedovati MC, Giustozzi M, Munoz A. et al. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism. Eur J Intern Med 2023; 112: 29-36
    CrossrefPubMedGoogle Scholar
  • 93 Verso M, Agnelli G, Munoz A. et al. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. Eur J Cancer 2022; 165: 136-145
    CrossrefPubMedGoogle Scholar
  • 94 Trujillo-Santos J, Nieto JA, Tiberio G. et al; RIETE Registry, Findings from the RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Thromb Haemost 2008; 100 (03) 435-439
    Article in Thieme ConnectPubMedGoogle Scholar
  • 95 Monreal M, Falgá C, Valdés M. et al; RIETE Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4 (09) 1950-1956
    CrossrefPubMedGoogle Scholar
  • 96 Martín AJM, Palacios ML, Souto JC. et al. Predicting major bleeding events in anticoagulated cancer patients with venous thromboembolism using real-world data and machine learning. J Clin Oncol 2022; 40 (16) e18744-e18744
    CrossrefPubMedGoogle Scholar
  • 97 McBane Ii RD, Vlazny DT, Houghton D. et al. Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment. Thromb Haemost 2023; 123 (05) 535-544
    Article in Thieme ConnectPubMedGoogle Scholar
  • 98 Mahé I, Chidiac J, Bertoletti L. et al; RIETE Investigators. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med 2017; 130 (03) 337-347
    CrossrefPubMedGoogle Scholar
  • 99 Cominacini M, Suardi S, Ferrari G. et al. DOAC in the treatment of cancer-associated venous thromboembolism: a retrospective cohort study beyond the guidelines. J Cancer Res Clin Oncol 2023; 149 (09) 5773-5779
    CrossrefPubMedGoogle Scholar
  • 100 Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10 (10) 967-974
    CrossrefPubMedGoogle Scholar
  • 101 Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010; 79 (1-2): 27-38
    CrossrefPubMedGoogle Scholar
  • 102 Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol 2018; 25 (05) 482-494
    CrossrefPubMedGoogle Scholar
  • 103 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. OncoTargets Ther 2018; 11: 5059-5074
    CrossrefPubMedGoogle Scholar
  • 104 Hang XF, Xu WS, Wang JX. et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011; 67 (06) 613-623
    CrossrefPubMedGoogle Scholar
  • 105 Patel SH, George TL, Wang TF. et al. Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. Cancer 2021; 127 (06) 938-945
    CrossrefPubMedGoogle Scholar
  • 106 Lipsky AH, Farooqui MZ, Tian X. et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 2015; 100 (12) 1571-1578
    CrossrefPubMedGoogle Scholar
  • 107 Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 2017; 15 (05) 835-847
    CrossrefPubMedGoogle Scholar
  • 108 Wang TF, Hill M, Mallick R. et al. The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies. Thromb Res 2023; 231: 128-134
    CrossrefPubMedGoogle Scholar
  • 109 Oyakawa T, Muraoka N, Iida K, Kusuhara M, Mori K. Use of direct oral anti-coagulants for the treatment of venous thromboembolism in patients with advanced cancer: a prospective observational study. Int J Clin Oncol 2019; 24 (07) 876-881
    CrossrefPubMedGoogle Scholar
  • 110 Tsigkas G, Vakka A, Apostolos A. et al. Dual antiplatelet therapy and cancer; balancing between ischemic and bleeding risk: a narrative review. J Cardiovasc Dev Dis 2023; 10 (04) 135
    PubMedGoogle Scholar
  • 111 de Winter MA, Dorresteijn JAN, Ageno W. et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022; 122 (05) 818-829
    Article in Thieme ConnectPubMedGoogle Scholar
  • 112 Hijazi Z, Oldgren J, Lindbäck J. et al; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387 (10035): 2302-2311
    CrossrefPubMedGoogle Scholar
  • 113 Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020; 120 (04) 702-713
    Article in Thieme ConnectPubMedGoogle Scholar
  • 114 Siguenza P, Lopez-Nunez JJ, Falga C. et al. Enoxaparin for long-term therapy of venous thromboembolism in patients with cancer and renal insufficiency. Thromb Haemost 2024; 124 (04) 363-373
    Article in Thieme ConnectPubMedGoogle Scholar
  • 115 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost . Nov 2015; 13 (11) 2119-26 DOI: 10.1111/jth.13140.
    CrossrefPubMedGoogle Scholar